AtM Foundation

The Access to Medicine (AtM) Foundation last week published a pediatric analysis of additional results from its 2021 AtM Index, finding just 7% of pharmaceutical companies’ R&D is for children under 12, despite significant gaps in treatment options for children.

The report praised GSK, Johnson & Johnson and Sanofi for being “the most active” in developing pediatric versions of products, and also named examples of drugs that “could each make a big difference” for LMICs: Eli…

For the seventh time in a row, GSK topped the Access to Medicine (AtM) Foundation’s ranking of leading pharma companies’ efforts to provide access to their products in low- and middle-income countries, according to the 2021 AtM Index, launched Tuesday. But the new index showed Novartis gaining on GSK compared to 2018—with the difference in scores falling to only 1.2%.

Overall, 17 of the 20 companies in the index improved their assessments, with Pfizer climbing the most to join the…

The Access to Medicine (AtM) Foundation and WHO released reports this month on efforts to combat antimicrobial resistance (AMR).

The AtM Foundation’s biennial evaluation of 30 pharmaceutical companies found “signs of progress,” but not yet at the scale needed to radically impact the threat of drug resistance.

Its 2020 Antimicrobial Resistance Benchmark praised companies for discouraging overuse of antibiotics and antifungals, preventing the release of antibacterial residue in…

The Access to Medicine (AtM) Foundation published its 2018 biennial ranking today of what leading pharma companies are doing to improve access to their products in low- and middle-income countries.

GSK topped the list for the sixth consecutive time since the index started in 2008, winning praise as the “most access-oriented” of the 20 companies measured and for its “long-standing foundation of projects, initiatives and policies.”

Novartis with its Novartis Access Principles rose…

The Access to Medicine (AtM) Foundation warned last week in a new white paper that global supply chains for antibiotics are on the brink of collapse.

Citing an ongoing penicillin shortage affecting at least 39 countries, among other problems, the AtM Foundation blamed the situation on overconcentration of manufacturing in too few factories, little commercial incentive for industry to invest in R&D, and complex supply chains.

The report said the international community should…